International pharmaceutical companies [should] not only look at Japan as a single country, but also as the gateway to Asia
In Conversation
Step-by-step, we are increasing the presence and engagement of Takeda Oncology Japan, leveraging the strength of our other therapeutic area business units, and stakeholders are increasingly…
We are confident that 2020 and 2021 will be very relevant years for regenerative medicine in Japan
The greatest strength of Molcure’s system is the ability to discover drugs that could never be found by using conventional methods
What is most important to stress is that there are many different applications for our technology, particularly in the field of regenerative medicine.
"Bio is something that Japan has not always been on the frontline of"
FIRM acts as a form of translational bridge between academia and the market, bringing the results of academia to the patient
The most important item, these past five years, has been winning the trust of the public, the industry and academia alike
We aim to stimulate the biomedical industry and our main mission is to fast-track medical R&D and improve three different types of lives: lifespan, daily life,…
"Despite Japan’s efforts to improve translational research and bring academia closer to the industry, bioIPSeeds actually perfectly embodies the kind of pioneering tool that could benefit…
